ENTA Earnings

Quarterly EPS
$-1.36
Q4 2024
$-1.05
Q1 2025
$-1.06
Q2 2025
$-0.85
Q3 2025
$-0.87
Q4 2025
$-0.42
Q1 2026
$-0.45
Q2 2026
$-0.67
Q3 2026
Latest Revenue14.4M
Latest Net Income-19501000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q3 2026-$0.6714.4M-19501000-21.6%+21.2%
Q2 2026-$0.4517.2M-13091000+15.0%+57.5%
Q1 2026-$0.4218.6M-11938000+9.8%+60.0%
Q4 2025-$0.8715.1M-18700000+3.5%+36.0%
Q3 2025-$0.8518.3M-18255000+1.9%+20.6%
Q2 2025-$1.0614.9M-22644000-12.5%+27.9%
Q1 2025-$1.0517.0M-22290000-5.8%+33.5%
Q4 2024-$1.3614.6M-28823000-18.9%+13.9%
Q3 2024-$1.0718.0M-22658000
Q2 2024-$1.4717.1M-31157000
Q1 2023-$1.5818.0M-33407000
Q1 2024-$1.5818.0M-33407000
Enanta Pharmaceuticals (ENTA) — Earnings